![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 2
Zeitschriftenartikel
Wyk, Jean van; Orkin, Chloe; Rubio, Rafael; Bogner, Johannes; Baker, David; Khuong-Josses, Marie-Aude; Parks, David; Angelis, Konstantinos; Kahl, Lesley P.; Matthews, Jessica; Wang, Ruolan; Underwood, Mark; Wynne, Brian; Nascimento, Maria-Claudia; Vandermeulen, Kati; Gartland, Martin und Smith, Kimberly Y.
(2020):
Brief Report: Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to Dolutegravir plus Rilpivirine 2-Drug Regimen: 148-Week Results From the SWORD-1 and SWORD-2 Randomized Clinical Trials.
In: Jaids-Journal of Acquired Immune Deficiency Syndromes, Bd. 85, Nr. 3: S. 325-330
Aboud, Michael; Orkin, Chloe; Podzamczer, Daniel; Bogner, Johannes R.; Baker, David; Khuong-Josses, Marie-Aude; Parks, David; Angelis, Konstantinos; Kahl, Lesley P.; Blair, Elizabeth A.; Adkison, Kimberly; Underwood, Mark; Matthews, Jessica E.; Wynne, Brian; Vandermeulen, Kati; Gartland, Martin und Smith, Kimberly
(2019):
Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1:100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies.
In: Lancet Hiv, Bd. 6, Nr. 9, E576-E587